Dose Insider / Glossary / Pancreatic cancer risk

Pancreatic cancer riskWhat trials and cohorts show for GLP-1 drugs

Updated November 20, 2026 路 3 min read 路 Figlioli 2024 meta-analysis of 90 trials; Dankner 2024 cohort; Wegovy label

Pancreatic cancer risk is one of the long-standing questions about GLP-1 medicines. Concerns were raised that these drugs might increase it, which is why large studies have looked for it.1 The two biggest recent analyses found no increase.

1.0590 trials, Pancreatic cancer, cancer risk ratios on GLP-1s
Cancer risk ratios on GLP-1sAgainst comparison groups; 1 means no difference90 TRIALSPancreatic cancer1.05Any gut cancer0.99Colorectal cancer1.13Stomach cancer0.88ISRAELI COHORT, YEARS 5 TO 7Pancreatic cancer0.50Cancer risk ratios on GLP-1sAgainst comparison groups; 1 means no difference90 TRIALSPancreatic cancer1.05Any gut cancer0.99Colorectal cancer1.13Stomach cancer0.88ISRAELI COHORT, YEARS 5 TO 7Pancreatic cancer0.50

None of these differences was statistically clear.

On this page

A 2024 review of 90 randomized trials put the risk ratio for pancreatic cancer at 1.05, and a 2024 cohort of 543,595 adults with type 2 diabetes found no support for a rise over 7 years.2,1

What the randomized trials show

The 2024 review pooled 90 randomized trials of GLP-1 medicines with 124,791 participants, followed for an average of 3.1 years each. It found no clear link with gut cancers as a group, a risk ratio of 0.99, or with any single site:2

A risk ratio of 1 means no difference from the comparison group, and every range above includes 1. The authors report that the absolute risk differences ruled out important effects, that the result held in placebo-controlled trials, high-dose studies and trials lasting 5 years or more, and that the certainty of the evidence was high.2

What a large cohort shows

The trials averaged 3.1 years; the 2024 Israeli study followed people for longer. It used records from Clalit, Israel's largest health organization, for 543,595 adults with new type 2 diabetes from 2009 to 2017, a total of 3,290,439 person-years. 1,665 of them were diagnosed with pancreatic cancer. 33,377, or 6.1%, used a GLP-1 medicine, and they were compared with 106,849 users of basal insulin. The average age was 59.9 and 51% were women. The comparison was adjusted for age, sex, ethnic background, social and economic status, starting BMI, smoking, past pancreatitis, other diabetes medicines and how long the person had had diabetes.1

To avoid reverse causation, where an early cancer not yet diagnosed affects which drug a person gets, the analysis focused on use 5 to 7 years earlier. The hazard ratio was 0.5, with a wide range from 0.15 to 1.71; two other designs gave 0.52 and 0.75. The authors found no support for a higher incidence over 7 years, and said that monitoring beyond 7 years is still needed.1

The limits of the evidence

The Israeli cohort included only adults with type 2 diabetes, compared GLP-1 users with users of basal insulin rather than with untreated people, and its follow-up ended in December 2017. Its ranges were wide: an upper end of 1.71 for years 5 to 7 does not rule out some increase. The study was registered as NCT02072902.1 The trials in the 2024 review lasted 3.1 years on average, and the review rated the certainty of its evidence as high.2

What the labels say

The Wegovy label does not list pancreatic cancer among its warnings. It does warn about acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing forms, observed in patients on GLP-1 medicines. The signs to watch for are persistent or severe abdominal pain, sometimes spreading to the back, with or without nausea or vomiting. If pancreatitis is suspected, the label says to stop Wegovy and start appropriate care.3 The one cancer the label names, in its boxed warning, is medullary thyroid carcinoma. Pancreatitis and pancreatic cancer are different conditions; our page on stomach pain on a GLP-1 covers the pain that should be checked.

Sources

  1. Dankner R, Murad H, Agay N, Olmer L, Freedman LS. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes. JAMA Netw Open 2024;7:e2350408. doi:10.1001/jamanetworkopen.2023.50408
  2. Figlioli G, Piovani D, Peppas S, et al. Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2024;208:107401. doi:10.1016/j.phrs.2024.107401
  3. WEGOVY (semaglutide) injection prescribing information. Novo Nordisk; DailyMed, version 19, published June 30, 2026; boxed warning and section 5. dailymed.nlm.nih.gov

Related analyses

Log stomach pain with its date and dose, so a doctor can see the pattern if it persists.

Open Dose Insider